Roger joined Samsara BioCapital as a Senior Analyst in 2020. Prior to joining Samsara, he completed his PhD in Molecular and Cellular Physiology at Stanford working with Thomas Südhof on the functions of synaptic adhesion molecules. Roger has consulted for numerous roles across the drug development industry, including company formation with ARCH Venture Partners, biotech venture capital with Hillhouse Capital, business development with Maze Therapeutics and clinical development with Merck KGaA. While at Stanford, he founded the Mythos Biotechnology Fund, a student-led public biotech investment club. Prior to his PhD, Roger worked in early-stage R&D at Roche. He obtained his BSc in Pharmacology from the University of British Columbia.